NeuroSense Therapeutics Ltd NRSN

NAS: NRSN | ISIN: IL0011809592 20/07/2026

0,690 USD (+0,80%)

(+0,80%) 20/07/2026

Grafiek NeuroSense Therapeutics Ltd

Grafiek NeuroSense Therapeutics Ltd

1 dag1d 0,80%
1 week1w -5,55%
1 maand1m -12,61%
3 maanden3m -0,07%
6 maanden6m -28,70%
1 jaar1j -64,27%
5 jaar5j -82,93%

NeuroSense Therapeutics Ltd in het nieuws

Toon enkel gratis nieuws

6 juli 2026 · NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" · Persbericht

29 juni 2026 · NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS · Persbericht

25 juni 2026 · NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease · Persbericht

22 juni 2026 · EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots · Persbericht

11 juni 2026 · NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS · Persbericht

9 juni 2026 · NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition · Persbericht

28 april 2026 · NeuroSense Announces Pricing of Insider-Led PIPE Financing · Persbericht

6 april 2026 · NeuroSense Granted Brazilian Patent Covering PrimeC Composition · Persbericht

3 april 2026 · NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements · Persbericht

31 maart 2026 · NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe